EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine

Hartmut Döhner iD, Keith W Pratz, Courtney D DiNardo iD, Andrew H Wei iD, Brian A Jonas iD, Vinod A Pullarkat, Michael J Thirman, Christian Récher iD, Andre C Schuh, Sunil Babu, Xiaotong Li, Grace Ku und 6 weitere

Blood · 21.11.2024 · 144 (21) · 2211-2222

DOI: 10.1182/blood.2024024944 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood, erschienen am 21.11.2024. Verfasst von Hartmut Döhner und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Azacitidine, Bridged Bicyclo Compounds, Heterocyclic, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 179-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The European LeukemiaNet (ELN) acute myeloid leukemia (AML) genetic risk classification systems are based on response to intensive chemotherapy; their ability to discriminate outcomes in older patients treated with venetoclax-azacitidine may be suboptimal. This pooled analysis of the phase 3 VIALE-A trial (NCT02993523) and phase 1b study (NCT02203773) examined prognostic stratification according to the 2017 and 2022 ELN risk classifications and derived new molecular signatures differentiating venetoclax-azacitidine–treated patients based on overall survival (OS). Overall, 279 patients treated with venetoclax-azacitidine and 113 patients treated with placebo-azacitidine were analyzed. The ELN 2017 or 2022 prognostic criteria classified most patients as adverse-risk AML (60.2% and 72.8% for venetoclax-azacitidine and 65.5% and 75.2% for placebo-azacitidine, respectively). Although outcomes with venetoclax-azacitidine improved across all ELN risk groups compared with placebo-azacitidine, ELN classification systems poorly discriminated venetoclax-azacitidine outcomes. By applying a bioinformatic algorithm, new molecular signatures were derived differentiating OS outcomes with venetoclax-azacitidine. The mutational status of TP53, FLT3 internal tandem duplication (FLT3-ITD), NRAS, and KRAS categorized patients into higher-, intermediate-, and lower-benefit groups (52%, 25%, and 23% of patients, respectively), each associated with a distinct median OS (26.5 months [95% confidence interval (CI), 20.2-32.7]; 12.1 months [95% CI, 7.3-15.2]; and 5.5 months [95% CI, 2.8-7.6], respectively). ELN prognostic classifiers did not provide clinically meaningful risk stratification of OS outcomes in patients treated with venetoclax-azacitidine. TP53, FLT3-ITD, NRAS, and KRAS mutation status allows the classification of these patients into 3 risk groups with distinct differences in median OS. These trials were registered at www.clinicaltrials.gov as #NCT02993523 and #NCT02203773.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsAzacitidineBridged Bicyclo Compounds, HeterocyclicLeukemia, Myeloid, AcuteSulfonamidesAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedMutationPrognosisRisk AssessmentTreatment OutcomeClinical Trials, Phase III as TopicClinical Trials, Phase I as TopicRandomized Controlled Trials as Topic

Substanzen

AzacitidineBridged Bicyclo Compounds, HeterocyclicSulfonamidesvenetoclax

Autor:innen und Institutionen

  • Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany.
  • Division of Hematology-Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
  • Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Department of Clinical Haematology, Peter MacCallum Cancer Centre, The Royal Melbourne Hospital, Walter and Eliza Hall Institute of Medical Research and The University of Melbourne, Melbourne, Australia.
  • Division of Malignant Hematology/Cellular Therapy and Transplantation, Department of Internal Medicine, University of California Davis School of Medicine, Sacramento, CA.
  • Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, CA.

ORCID-Profile: Hartmut Döhner, Courtney D DiNardo, Andrew H Wei, Brian A Jonas, Christian Récher, Yan Sun, Daniel A Pollyea

Förderung

  • NCI NIH HHS

Zitieren

APA

Döhner, H., Pratz, K. W., DiNardo, C. D., Wei, A. H., Jonas, B. A., Pullarkat, V. A., Thirman, M. J., Récher, C., Schuh, A. C., Babu, S., Li, X., Ku, G., Liu, Z., Sun, Y., Potluri, J., Dail, M., Chyla, B., & Pollyea, D. A. (2024). Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine. Blood, 144(21), 2211-2222. https://doi.org/10.1182/blood.2024024944

Vancouver

Döhner H, Pratz KW, DiNardo CD, Wei AH, Jonas BA, Pullarkat VA, et al. Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine. Blood. 2024;144(21):2211-2222. doi:10.1182/blood.2024024944

BibTeX
@article{Dhner2024,
  author = {Döhner, Hartmut and Pratz, Keith W and DiNardo, Courtney D and Wei, Andrew H and Jonas, Brian A and Pullarkat, Vinod A and Thirman, Michael J and Récher, Christian and Schuh, Andre C and Babu, Sunil and Li, Xiaotong and Ku, Grace and Liu, Zihuan and Sun, Yan and Potluri, Jalaja and Dail, Monique and Chyla, Brenda and Pollyea, Daniel A},
  title = {Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine},
  journal = {Blood},
  year = {2024},
  volume = {144},
  number = {21},
  pages = {2211--2222},
  doi = {10.1182/blood.2024024944}
}
Kostenlos starten →